According to Expertscape, Dr. Bergantin equates to the top-rated expert in cyclic AMP in the USA during the years 2013-2023. In fact, Dr. Bergantin has been recognized by the website Expertscape.com as "World Expert" in ´cyclic AMP´ (#2 world ranking Expertscape, 2013-23). The recognition as "World Expert" is a particularly noteworthy distinction, since Expertscape uses the data from the National Institute of Health’s PubMed database to identify and objectively rank physicians and researchers as experts on a specific topic. Dr. Bergantin has also been recognized by Expertscape as "Expert" in ´calcium´ (2013-23). To be considered an Expertscape “Expert”, the researcher needs to be ranked among the top 1% worldwide in research and publications in a specific medical topic, and to be recognized as an Expertscape “World Expert” requires the top 0.1% worldwide. Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil): biomedicine (2008), MSc (2010) and PhD (2014); with research visiting period in UAM (Spain). In 2024, Dr. Bergantin also received an MD degree. His research involves cell signalling mediated by calcium (Ca2+) and cyclic AMP (cAMP), including its role in neuropsychopharmacology, autonomic and cardiovascular pharmacology, diabetes, and cancer. Dr. Bergantin´s research work solved the enigma of the paradoxical effects produced by L-type Ca2+ channel blockers (CCB), which was published in Cell Calcium (JCR: 4.3, CiteScore: 8.7) and achieved the position ´ScienceDirect TOP 25 Hottest Articles´ (ranked #1 on the TOP 25 for Cell Calcium, 2013). This discovery generated 31 articles published in international journals indexed in PubMed, in which 25 of them Dr. Bergantin is the sole author. Dr. Bergantin is Review Editor of Frontiers in Neuroscience (JCR: 3.2), Frontiers in Neurology (JCR: 2.7), Frontiers in Pharmacology (JCR: 4.4), Frontiers in Psychiatry (JCR: 3.2), Frontiers in Neuroanatomy (JCR: 2.1). Dr. Bergantin has also been appointed Editor of the World Journal of Psychiatry (JCR: 3.9). Briefly, since 1970s several studies have shown that low doses of CCB paradoxically enhanced the contractions of smooth muscles. In 2013, Dr. Bergantin discovered that this paradoxical phenomenon is related to the interaction of Ca2+/cAMP signalling, then opening new avenues for biomedical research, e.g., neurological and psychiatry diseases, cancer, diabetes, and asthma. This discovery opened new avenues for biomedical research, e.g. 1) the pharmacological manipulation of this interaction could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders, and producing neuroprotection in the neurodegenerative diseases; 2) the pharmacological handling of the Ca2+/cAMP signalling interaction could be an adjuvant therapeutic approach to inhibit cancer tumor progression; 3) the pharmacological handling of the Ca2+/cAMP signalling interaction could be an adjuvant therapeutic approach to stimulate the release of hormones, e.g. insulin in diabetes; 4) the pharmacological manipulation of this interaction could be a new therapeutic strategy for stimulating anti-inflammatory signals (e.g. increasing cAMP levels) as well as reducing proinflammatory processes (e.g. decreasing Ca2+ levels); 5) Ca2+/cAMP ratio could serve as an inflammatory index. Dr. Bergantin is member of several editorial boards of international journals and has been frequently invited to be honorable guest in international conferences.